• Profile
Close

New imaging agent may guide therapy for brain diseases

IANS Apr 04, 2018

Scientists have developed a new imaging method that can guide and assess treatment strategies for people diagnoses with neurological diseases.


Researchers have developed a new imaging agent that could help guide and assess treatments for people with various neurological diseases, including Alzheimer's, Parkinson's and Multiple Sclerosis (MS). The agent, which is used in PET scans, targets receptors in nerve cells in the brain that are involved in learning and memory. "The significance of the work lies in the fact that we have for the first time developed a useful PET 'radioligand' (a radioactive bio-chemical substance) that can be applied to image the 'GluN2B' receptor subunit of the 'NMDA' receptor complex in humans," said co-author Simon M. Ametamey from the Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland.

For the study, published in The Journal of Nuclear Medicine, the agent was used in live rats to investigate the dose and effectiveness of "eliprodil" -- a drug that blocks the "NMDA GluN2B" receptor. PET scans with the new "radioligand" successfully showed that the receptors are fully occupied at neuro-protective doses of "eliprodil". "These results mean that a new radio-pharmaceutical tool is now available for studying brain disorders such as Alzheimer's disease, Parkinson's disease and MS, among others," Ametamey said.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay